Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin

NCT07061080 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.

NCT NCT07061080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07061080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Phase 2
Overall status
Terminated
Start date
December 18, 2025
Completion date
September 3, 2026
Enrollment
1 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced neuroendocrine carcinomas of the digestive system, advanced neuroendocrine carcinomas unknown primary origin